Rituximab: A new therapeutic monoclonal antibody for non-Hodgkin's lymphoma

被引：74
|
作者：
Scott, SD [1 ]
机构：
[1] Univ Iowa, Coll Pharm, Div Clin & Adm Pharm, Iowa City, IA 52242 USA
来源：
CANCER PRACTICE | 1998年 / 6卷 / 03期
关键词：
D O I：
10.1046/j.1523-5394.1998.006003195.x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：195 / 197
页数：3
相关论文
共 50 条
  • [21] TREATMENT OF NON-HODGKIN LYMPHOMA WITH UNIVALENT MONOCLONAL ANTIIDIOTYPIC ANTIBODY
    WORSLEY, A
    HAMBLIN, TJ
    GLENNIE, M
    MUFTI, GJ
    SMITH, J
    STEVENSON, FK
    STEVENSON, GT
    BRITISH JOURNAL OF HAEMATOLOGY, 1986, 64 (04) : 820 - 820
  • [22] Antibody therapy with Rituximab for patients with low-grade non-Hodgkin's lymphoma
    Dallaire, BK
    Deardorff, JA
    White, CA
    Dowden, S
    Varns, C
    Shen, D
    Grillo-López, AJ
    ONKOLOGIE, 1999, 22 (03): : 184 - 190
  • [23] Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
    Leonard, JP
    Coleman, M
    Ketas, J
    Ashe, M
    Fiore, JM
    Furman, RR
    Niesvizky, R
    Shore, T
    Chadburn, A
    Horne, H
    Kovacs, J
    Ding, CL
    Wegener, WA
    Horak, ID
    Goldenberg, DM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 5044 - 5051
  • [24] Antibody therapy for non-Hodgkin's lymphoma
    Ansell, SM
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2004, 6 (02) : 175 - 181
  • [25] Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma
    Hainsworth, JD
    Burris, HA
    Morrissey, LH
    Litchy, S
    Scullin, DC
    Bearden, JD
    Richards, P
    Greco, FA
    BLOOD, 2000, 95 (10) : 3052 - 3056
  • [26] Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review
    Fallahi, Mohammad Sadegh
    Zerangian, Nasibeh
    Ghorbani, Atousa
    Erabi, Gisou
    Shirali, Melika
    Shabani, Elaheh
    Rommasi, Foad
    Najafabadi, Mahsa Mohammadi
    Karbasi, Shima
    Toutounchian, Samaneh
    Ahangar-Sirous, Ramin
    Motaghy, Ava
    Heidari, Mahsa
    Deravi, Niloofar
    CURRENT CANCER THERAPY REVIEWS, 2024, 20 (01) : 53 - 99
  • [27] New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma
    Rossi, C.
    Bastie, J. N.
    REVUE DE MEDECINE INTERNE, 2019, 40 (04): : 246 - 254
  • [28] Sequential treatment of non-Hodgkin's lymphoma (NHL) with radiolabeled LYM-1monoclonal antibody (MAB) and rituximab.
    O'Donnell, RT
    Wun, T
    Wilbur, P
    Tuscano, JM
    BLOOD, 1999, 94 (10) : 266B - 266B
  • [29] Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma:: Results of a phase II trial of rituximab
    Davis, TA
    White, CA
    Grillo-López, AJ
    Velásquez, WS
    Link, B
    Maloney, DG
    Dillman, RO
    Williams, ME
    Mohrbacher, A
    Weaver, R
    Dowden, S
    Levy, R
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) : 1851 - 1857
  • [30] Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma
    Fanale, Michelle A.
    Younes, Anas
    DRUGS, 2007, 67 (03) : 333 - 350
12345